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Catecholamines promote lipolysis both in brown and
white adipocytes, whereas the same stimuli prefer-
entially activate thermogenesis in brown adipocytes.
Molecular mechanisms for the adipose-selective
activation of thermogenesis remain poorly under-
stood. Here, we employed quantitative phosphopro-
teomics tomap global and temporal phosphorylation
profiles in brown, beige, and white adipocytes under
b3-adrenenoceptor activation and identified kinases
responsible for the adipose-selective phosphoryla-
tion profiles. We found that casein kinase2 (CK2) ac-
tivity is preferentially higher in white adipocytes than
brown/beige adipocytes. Genetic or pharmacolog-
ical blockade of CK2 in white adipocytes activates
the thermogenic program in response to cAMP stim-
uli. Such activation is largely through reduced CK2-
mediated phosphorylation of class I HDACs. Notably,
inhibition of CK2 promotes beige adipocyte biogen-
esis and leads to an increase in whole-body energy
expenditure and ameliorates diet-induced obesity
and insulin resistance. These results indicate that
CK2 is a plausible target to rewire the b3-adreneno-
ceptor signaling cascade that promotes thermogen-
esis in adipocytes.
INTRODUCTION
A chronic imbalance between energy intake and energy expen-
diture leads to the development of obesity and metabolic dis-
eases, including type 2 diabetes. While decreasing food intake
and increasing physical activity constitute logical ways to tip en-
ergy balance toward weight loss in the short term, effective and
alternative approaches arewarranted for long-termmaintenance
of proper body weight. Since the prevalence of brown adipose
tissue (BAT) and its contribution to energy homeostasis have
been widely appreciated in adult humans, it is considered that
increasing BAT-mediated thermogenesis via uncoupling proteinCell Me1 (UCP1) serves as an alternative approach to modulate energy
balance (reviewed in Sidossis and Kajimura, 2015).
Recent studies suggest that rodents and humans possess at
least two populations of UCP1-positive thermogenic adipocytes:
classical brown adipocytes and beige adipocytes (or brite
cells). Beige adipocytes reside sporadically within white adipose
tissue (WAT) where they emerge in response to certain external
stimuli, such as chronic cold exposure, exercise, and long-
term treatment with PPARg agonists. This phenomenon is often
referred to as the ‘‘browning’’ of WAT (reviewed in Harms and
Seale, 2013; Kajimura and Saito, 2014). Recent studies using
18F-fluoro-2-deoxy-d-glucose positron emission tomography
computed tomography (18F-FDG-PET/CT) scans found that
adult human BAT can be recruited after chronic cold exposure
even in subjects who do not possess appreciable amounts of
BAT depots before cold exposure; this recruitment of BAT
is accompanied by an increase in energy expenditure and
improved postprandial insulin sensitivity (Lee et al., 2014a; van
der Lans et al., 2013; Yoneshiro et al., 2013). Furthermore, mo-
lecular analyses indicate that adult human BAT contains beige-
like adipocytes (Cypess et al., 2013; Lee et al., 2014b; Lidell
et al., 2013; Sharp et al., 2012; Shinoda et al., 2015; Wu et al.,
2012; Xue et al., 2015). For instance, RNA-sequencing analyses
of clonal adult human brown adipocytes indicate that their gene
signatures resemble murine beige adipocytes (Shinoda et al.,
2015). These results further emphasize the potential importance
of beige adipocytes in human obesity and metabolic diseases.
Stimulation of b-adrenoceptor (b-AR) is a major physiological
stimulus of adipocyte lipolysis in response to cold exposure.
Catecholamines released from the sympathetic nerve terminals
binds to b-ARs and increases intracellular cAMP levels. The in-
crease in cAMP levels activates protein kinase A (PKA), fol-
lowed by phosphorylation of hormone-sensitive lipase (HSL)
and perilipin (PLIN), which stimulates lipolysis in white, brown,
and beige adipocytes (Collins, 2011; Duncan et al., 2007). Pre-
vious studies have shown that PKA phosphorylation followed by
p38MAPK activation induces the program, such as Ucp1 via
p38MAPK-mediated phosphorylation of ATF2 and PGC-1a
(reviewed in Collins, 2011). However, molecular mechanisms,
for which the b-AR signaling pathway preferentially promotes
thermogenesis in brown and beige adipocytes, remain poorly
understood.tabolism 22, 997–1008, December 1, 2015 ª2015 Elsevier Inc. 997
Figure 1. Identification of CK2 as a White
Adipocyte-Selective Kinase Activated in
Response to Norepinephrine and to a High-
Fat Diet
(A) Schematic of phosphoproteomic analysis in
brown, beige, and white adipocytes.
(B) Hierarchical clustering and heatmap of phos-
phoproteome in brown adipocytes, white adipo-
cytes (F442A), and beige adipocytes (F442A
expressing PRDM16). Each column represents
sample, and each row represents phosphorylated
protein. The color scale shows the numbers of
phosphorylation sites per phosphoprotein in blue
(low) to yellow (high) color scheme.
(C) Hierarchical clustering and heatmap of
phosphoproteome in primary brown adipocytes,
inguinal white adipocytes, and beige adipocytes
(inguinal adipocytes treated with rosiglitazone).
The color scale shows the peak intensity of phos-
phopeptides in log2 scale. The values are average
of three measurements per sample.
(D) Phosphopeptide motif analysis of brown,
beige, and white adipocytes. Brown bars repre-
sent p values by repeated-measures ANOVA to
show the difference in phosphoproteome con-
taining the indicated kinase motif between brown
and white adipocytes. Beige bars represent the
difference between beige and white adipocytes.
(E) Temporal dynamics of CK2 activity in brown,
beige, and white adipocytes in response
to norepinephrine treatment. Inset shows the
conserved CK2-motif peptide sequences found in
the phosphoproteome. n = 4.
(F) CK2 activity in the inguinal WAT of mice under a
regular chow diet or a high-fat diet. n = 10.
(G) CK2 activity in the inguinal WAT, epidydimal/
WAT, and interscapular BAT of mice under a
regular chow diet and a high-fat diet for 16 weeks.
*p < 0.05, and **p < 0.01 by one-sided Student’s
t test.Here, we employed phosphoproteomics to map global and
temporal protein phosphorylation profiles in brown, beige,
and white adipocytes in response to norepinephrine treat-
ment. In contrast to conventional approaches using phosphor-
ylation-specific antibodies, recent advances in proteomics
technology allow for comprehensive profiling of protein phos-
phorylation from limited amounts of materials and for identi-
fying novel functions of kinases even in seemingly well-studied
signaling pathways (Blagoev et al., 2004; Kru¨ger et al., 2008;
Olsen et al., 2006). We unexpectedly found that Casein
Kinase 2 (CK2), an evolutionarily-conserved serine/threonine
kinase, is activated by norephinephrine stimulation preferen-
tially in white adipocytes. Notably, blockade of CK2 by
genetic or pharmacological approaches promotes the cAMP-
induced thermogenesis in white adipocytes. Furthermore,
inhibition of CK2 promotes beige adipocyte biogenesis in vivo
and protects mice from diet-induced obesity and insulin
resistance. These data provide insights on the physiological
role of CK2 in the regulation of brown/beige adipocyte-
selective thermogenesis and also illuminate the therapeutic998 Cell Metabolism 22, 997–1008, December 1, 2015 ª2015 Elseviepotential of CK2 inhibitors in combating obesity and obesity-
related diseases.
RESULTS
Phosphoproteomic Profiling of Brown, Beige, and White
Adipocytes
To identify the downstream signaling pathways of norepineph-
rine that are unique to brown, beige, and white adipocytes, we
devised a strategy as illustrated in Figure 1A. In brief, norepi-
nephrine was added into differentiated immortalized brown adi-
pocytes, white adipocytes (F442A cells), and a model of beige
adipocytes in which PRDM16 is ectopically expressed in
F442A adipocytes. The beige adipocytes express high levels of
Ucp1 and Pgc1a expression in response to cAMP stimuli, and
low levels of WAT-selective genes (Kajimura et al., 2008).
Additionally, primary stromal vascular fractions (SVFs) from the
interscapular BAT and inguinal WAT were differentiated under
a proadipogenic condition. Beige adipocyte differentiation was
induced using rosiglitazone as previously reported (Ohno et al.,r Inc.
2012). The differentiated adipocytes were harvested before the
treatment (time point 0) and at 5, 10, and 20 min after norepi-
nephrine treatment. Phosphorylated proteins from each cell
type were analyzed by liquid chromatography coupled with
tandem mass spectrometry (LC-MS/MS). Subsequently, the
identified phosphopeptides were computationally analyzed to
predict the kinases responsible for the adipose-selective phos-
phorylation profiles.
To compare phosphorylation profiles, hierarchical clustering
was applied based on the numbers of phosphorylation sites
per phosphoprotein. The clustering analysis in Figure 1B found
that expression of PRDM16 in F442A white adipocytes dramat-
ically changed the phosphorylation profile of white adipocytes
to a profile resembling that of brown adipocytes. The complete
phosphoproteome data sets are found in Table S1 available
online. In primary adipocytes, the phosphoproteome profile of
beige adipocytes resembles that of classical brown adipocytes
even when we applied the hierarchical clustering based on the
phosphopeptide peak intensity (Figure 1C). These analyses
capture the downstream signaling events of norepinephrine
that are unique to thermogenic adipocytes (i.e., brown and beige
adipocytes).
CK2 Pathway Is Preferentially Activated in White
Adipocytes in Response to Norepinephrine and to an
Obesogenic Diet
To predict kinases responsible for the adipose-selective phos-
phorylation profile, we first searched for conserved phospho-
peptide motifs from the above phosphoproteome. Next, the
PhosphoMotif finder database (Amanchy et al., 2007) was
applied to predict kinase families that were known to phosphor-
ylate such phosphopeptide motifs. Next, relative activities of the
predicted kinases were quantified by counting the consensus
phosphopeptide motifs at each time point. These analyses iden-
tified five kinases, including extracellular signal-related kinase
(ERK1/2), CK2, glycogen synthase kinase-3 (GSK-3), cyclin divi-
sion cycle 2 (CDC2), and PKA that were significantly different
between brown versus white adipocytes (Figure 1D). Of note,
previous studies report that norepinephrine activates Erk1/2
(Lindquist and Rehnmark, 1998; Shimizu et al., 1997; Valladares
et al., 2000) and PKA (Cao et al., 2001; Fredriksson et al., 2001)
signaling in brown adipocytes. Similarly, four kinases, including
CK2, AKT, CDC2, and ribosomal S6 kinase alpha3 (RKS2), dis-
played significantly different profiles in beige versus white adipo-
cytes. Among them, CK2 exhibited differential activity between
thermogenic adipocytes versus white adipocytes. As shown in
Figure 1E, levels of the CK2 motif-containing phosphopeptides
were dramatically increased in white adipocytes, but not in
brown adipocytes, in response to norepinephrine treatment.
This increase was seen in a much lesser extent in beige adipo-
cytes than white adipocytes. Temporal phosphorylation patterns
of PKA, GSK3 andCDC2 are shown in Figure S1A. A similar trend
of the CK2 phosphopeptide profile was observed in primary
adipocytes (Figure S1B).
To examine if CK2 is regulated under obesity, CK2 activity was
measured in the adipose tissues ofmice under a high-fat diet or a
regular diet. While no difference was observed at 4 weeks of
high-fat diet, CK2 activity was significantly increased in the
inguinal and epididymal WAT at 8 and 16 weeks of high-fatCell Mediet as compared to those under a regular diet (Figures 1F and
S2A). Importantly, such an increasewas selective to theWATde-
pots, as CK2 activity was not changed in the interscapular BAT
(Figure 1G). The obesity-associated increase in CK2 activity oc-
curs primarily in SVFs (Figure S2B), although no significant
change was observed in the SFVs fromWAT after cold exposure
(Figure S2C). Higher CK2 activity under obesity was due, in part,
to an increase in mRNA expression of Ck2a1, Ck2a2, and Ck2b
(Figure S2D), as CK2 activity is highly regulated at the level of
Ck2a gene expression (Allende and Allende, 1995; Li et al.,
1999). These results indicate that the CK2 pathway is activated
preferentially in WAT in response to an obesogenic diet and
norepinephrine.
Depletion of CK2 Activates the cAMP-Induced
Thermogenic Program in White Adipocytes
CK2 is a serine/threonine kinase that is composed of catalytic
subunits (a1 and a2) and two regulatory b subunits. To examine
the roles of CK2 in the regulation of adipocyte thermogenesis,
each CK2 subunit was depleted by RNAi in inguinalWAT-derived
immortalized white adipocytes. ThemRNA levels of a1, a2, and b
subunits were significantly decreased by 76%, 74%, and 77%,
respectively (Figure 2A). Notably, depletion of the major catalytic
component of CK2 (Ck2a1) significantly increased Ucp1 and
Pgc1a mRNA expression when differentiated white adipocytes
were stimulated with forskolin (Figure 2B). Depletion of Ck2a2
also increased Ucp1 expression, albeit moderately. Knockdown
of Ck2b subunit significantly impaired adipogenesis, as as-
sessed by Fabp4 expression. Of note, Ucp1 expression was
robustly induced by forskolin treatment in the Ck2a1-depleted
white adipocytes in a dose-dependent fashion (Figure 2C).
Ck2a1 knockdown also increased expression of the brown/
beige fat-selective genes, such as Cidea, Cited1, Cox8b, and
Elov3, without affecting the expression of Fabp4 (Figure 2D).
Higher UCP1 protein expression was observed in the Ck2a1-
depleted white adipocytes under cAMP stimulation (Figure 2E),
which lead to a significant increase in total and oligomycin-
insensitive cellular respiration (Figure 2F). These results suggest
that CK2 acts as a negative regulator of cAMP-induced thermo-
genesis in white adipocytes.
Pharmacological Inhibition of CK2 Promotes Beige
Adipocyte Biogenesis In Vivo
To ask if blockade of CK2 promotes the thermogenic program in
WAT in vivo, we administrated a potent and selective CK2 inhib-
itor, CX-4945, in mice under ambient temperature. CX-4945 is a
newly developed orally available ATP-competitive inhibitor for
CK2a1 and CK2a2 catalytic subunits, which has a strong anti-
tumor efficacy in breast cancers, pancreatic cancers, prostate
cancers, glioblastoma, and chronic lymphocytic leukemia
(Bliesath et al., 2012; Martins et al., 2014; Siddiqui-Jain et al.,
2010; Son et al., 2013; Zheng et al., 2013). As shown in Figure 3A,
CK2 activity in the inguinal WAT was significantly reduced
by 63% after a 5 day treatment at 50 mg kg1. Although CX-
4945 is reported to inhibit fetal liver kinase 2 (Flt3) at a higher
dose (Siddiqui-Jain et al., 2010), Flt3 expression was not de-
tected in adipose tissues (Figure S3A). Hence, CX-4945 is pri-
marily through inhibition of CK2 in adipose tissues. As shown
in Figure 3B, pharmacological inhibition of CK2 by CX-4945tabolism 22, 997–1008, December 1, 2015 ª2015 Elsevier Inc. 999
Figure 2. Depletion of CK2 Activates the
cAMP-Induced Thermogenic Program in
White Adipocytes
(A) Expression of Ck2a1, Ck2a2, and Ck2b in
inguinal adipocytes transfected with siRNAs tar-
geting the indicated subunits or non-targeting
control (Ctrl). n = 3.
(B) Expression of thermogenic and adipogenic
genes in inguinal white adipocytes depleted with
each CK2 subunit. The cells were treated with
forskolin at 10 mM for 4 hr to activate thermogen-
esis. n = 3.
(C) Ucp1 expression in inguinal white adipocytes
transfected with Ck2a1-targeting or control
siRNAs. Differentiated cells were treated with for-
skolin at 1, 10, and 50 mM for 4 hr. n = 3.
(D) Expression of brown/beige fat-selective genes
in inguinal white adipocytes transfected with
Ck2a1-targeting or control siRNAs. n = 3.
(E) Western blotting for UCP1 in inguinal white
adipocytes transfected with Ck2a1-targeting or
control siRNAs. Differentiated cells were treated
with forskolin at 10 mM for 8 hr. b-actin was used as
a loading control.
(F) Cellular oxygen consumption rate (OCR) in
inguinal white adipocytes transfected with Ck2a1-
targeting or control siRNAs. Differentiated cells
were treated with forskolin at 10 mM. n = 8.
*p < 0.05, **p < 0.01, ***p < 0.001 by one-sided
Student’s t test.significantly increased mRNA expression of Ucp1, Dio2, Pgc1a,
Elovl3, Cited1, Otop1, and Cidea in the inguinal WAT. The in-
crease in Ucp1 mRNA by CK2 inhibition was accompanied by
an increase in UCP1 protein expression in the inguinal WAT (Fig-
ure 3C). We also observed a moderate increase in UCP1 mRNA
and protein expression in the interscapular BAT (Figures 3C and
S3B). Importantly, the inguinal WAT of mice treated with CX-
4945 contained abundant clusters of UCP1-positive beige adi-
pocytes with multilocular lipid droplets as compared to that of
vehicle-treated mice (Figures 3D and 3E).
To ask if the CK2 inhibitor acts in a cell-autonomous fashion,
inguinal white preadipocytes were differentiated in the presence
of two distinct classes of CK2 inhibitor, CX-4945 and CK2-VIII.
Consistent with the knockdown studies, pharmacological inhibi-
tion of CK2 by CX-4945 significantly increased Ucp1 expression
in the presence of forskolin (Figure 3F). CK2-VIII is a highly selec-
tive CK2 inhibitor with a distinct chemical structure from CX-
4945, and potently inhibits CK2 activity with IC50 1.6–2.6 mM in
cultured cells (Hou et al., 2012). We found that Ucp1 mRNA
expression was significantly higher in the inguinal white adipo-
cytes treated with CK2-VIII at 1 mM (Figure 3F). Of note, the in-
crease in Ucp1 expression by CK2-VIII was completely blunted
when endogenousCk2a1was depleted in white adipocytes (Fig-1000 Cell Metabolism 22, 997–1008, December 1, 2015 ª2015 Elsevier Inc.ure S3C), indicating that the cell-autono-
mous action of CK2-VIII is largely
mediated by CK2. In addition to Ucp1,
CX-4945 and CK2-VIII increased several
brown/beige fat-selective genes, includ-
ing Pgc1a, Cidea, Elov3, and Cited1,
without affecting Fabp4 expression (Fig-ures 3G and 3H). CK2-VIII treatment also significantly increased
total and oligomycin-insensitive cellular respiration when cells
were stimulated with cAMP (Figure S3D). There appears to be
no major change in PKA signaling by CK2 inhibition, because
CKII-VIII did not change the phosphopeptide levels of major
PKA targets in adipocytes, including HSL and PLIN1 (Figures
S3E and S3F). Collectively, these data indicate that pharmaco-
logical inhibition of CK2 in white adipocytes activates the
cAMP-induced thermogenic program in a cell-autonomous
fashion.
CK2 Blockade Promotes Thermogenesis in White
Adipocytes through Reduced CK2-Mediated
Phosphorylation of Class I HDACs
To understand the mechanisms by which CK2 inhibition pro-
motes cAMP-induced thermogenesis in white adipocytes, we
employed phosphoproteomics to identify downstream media-
tors of CK2 in inguinal white adipocytes that were treated with
CK2-VIII and forskolin. Hierarchical clustering analysis, as deter-
mined by the abundance of phosphorylation sites, identified
a distinct cluster in which phosphorylation was significantly
decreased by CK2-VIII (i.e., CK2-dependent phosphoproteins)
(Figure 4A, left). The cluster was further divided into two groups
Figure 3. Pharmacological Inhibition of CK2
Promotes Beige Adipocyte Biogenesis
In Vivo
(A) CK2 activity in the inguinal WAT of mice treated
with vehicle or CX-4945 at 50 mg kg1 twice daily
for 5 days. n = 5.
(B) Expression of brown/beige fat-selective genes
in the inguinal WAT of mice treated with vehicle or
CX-4945 for 5 days. n = 5.
(C) Western blotting for UCP1 in the interscapular
BAT and inguinal WAT in (B). b-actin was used as a
loading control.
(D) H&E staining of the inguinal WAT of mice
treated with vehicle or CX-4945. Bottom shows
high-magnification images. Scale bar, 100 mm.
(E) UCP1 immunostaining (red) of the inguinal WAT
in (D). DAPI (white) was used to stain nuclei. Scale
bar, 70 mm.
(F) Dose-dependent increase in Ucp1 mRNA
expression in inguinal white adipocytes treated
with CX-4945 at 20 nM and 100 nM (top) and
CK2-VIII at 0.1 and 1 mM (bottom). Differentiated
adipocytes were treated with 10 mM forskolin for
4 hr. n = 3.
(G) Expression of brown/beige adipocyte-selective
genes in cultured inguinal white adipocytes treated
with CX-4945 at 100 nM. n = 3.
(H) Expression of brown/beige adipocyte-selective
genes in cultured inguinal white adipocytes treated
with CK2-VIII at 1 mM. n = 3. *p < 0.05, **p < 0.01,
***p < 0.001 by one-sided Student’s t test.in which phosphorylation was increased or decreased/un-
changed by cAMP. Z-score intensities of the cAMP-stimulated
cell were, on average, higher than control cells by 1.61, whereas
the difference in the second cluster was 1.04. When the CK2-
dependent phosphoproteins were overlapped with the phos-
phoproteome from brown, beige, and white adipocytes (shown
in Figure 1B), we found that a large part of the CK2-dependent
phosphoproteins was substantially lower in beige adipocytes
(59.7%) as well as in brown adipocytes (61.1%), as compared
to white adipocytes (Figure 4A, right panel). These results further
support the notion that CK2 is a major regulator of the white
adipocyte-selective phosphoprotein profile.
To identify direct CK2 substrates in white adipocytes, we per-
formed in vitro kinase assays using white adipocyte-derived pro-
tein extracts, as illustrated in Figure 4B. The phosphoproteome
analysis identified approximately 800 phosphorylated proteins
in which 219 proteins were enriched in at least one GeneCell Metabolism 22, 997–1008, DOntology (GO) (Table S2). The GO anal-
ysis found that 46% of them were linked
to cell cycle control, in addition to
apoptosis (22%), ubiquitination proteoly-
sis (19%), PI3K/AKT signaling (9%), and
DNA methylation/transcription (4%) (Fig-
ure 4C). Importantly, a large part (52.8%,
308/583 proteins) of the CK2-dependent
phosphoproteins found in cultured white
adipocytes were direct targets of CK2
(Figure 4D). Among the putative CK2 sub-
strates, we found that phosphorylation ofclass I HDACs (HDAC1 and HDAC2) was reduced by the CK2 in-
hibitor (Figure 4E). Specifically, three phosphorylated sites in
HDAC1 at serines 393, 421, and 423 and two sites in HDAC2
at serines 422 and 424 exhibited significant changes in a CK2-
dependent fashion (Figure 4F). These serine sites are evolution-
arily conserved among mammalian species (Figure 4G). CK2 is
known to phosphorylate HDAC2 at serines 394, 422, and 424
(Eom et al., 2011; Tsai and Seto, 2002), and mutations of
HDAC1 at serines 421 and serine 423 to alanine reduce enzy-
matic activity and complex formation (Pflum et al., 2001).
Since inhibition of class I HDACs is known to increase PGC1a
expression and oxidative metabolism (Galmozzi et al., 2013), we
hypothesized that class I HDACs mediate the CK2-linked adipo-
cyte thermogenesis. To test this, inguinal white adipocytes were
incubated with CK2-VIII in the presence or absence of a class I
HDAC-selective inhibitor, Mocetinostat. Similarly, the cells
were cotreated with Tubastatin, a selective inhibitor of HDAC6ecember 1, 2015 ª2015 Elsevier Inc. 1001
Figure 4. CK2 Blockade Activates Thermo-
genesis in White Adipocytes through
Reduced CK2-Mediated Phosphorylation of
Class I HDACs
(A) CK2-dependent phosphoproteome in white
adipocytes. The color scale shows z-scored peak
area of phosphopeptides in blue (low) to white to
red (high) scheme. Pie charts show overlaps in the
phosphoproteome between CK2 inhibitor-treated
white adipocytes and beige adipocytes (up) or
between CK2 inhibitor-treated white adipocytes
and classical brown adipocytes (bottom).
(B) Schematic of in vitro CK2 substrate profiling by
LC-MS/MS.
(C) GO analysis of phosphoproteins identified by
in vitro CK2 substrate profiling in white adipocytes.
The area of each pie slice represents the number
of proteins that belong to the enriched GO terms
(p < 0.01).
(D) Venn diagram of the overlapped phosphopro-
teins identified by in vivo assay in (A) and in vitro
CK2 substrate profiling in (B).
(E) Phosphorylation status of class I HDACs in
white adipocytes treated with CK2-VIII for 4 days.
CK2-mediated phosphorylation of HDAC1 or
HDAC2 was assessed by immunoprecipitation of
respective antibodies followed by western blotting
for phosphorylated CK2-substrate motifs. Total
HDAC1 and HDAC2 proteins (input) were shown in
the bottom panels. The HDAC-immunoprecipi-
tates and input were derived from the identical
samples and loaded into the separate gels.
(F) Quantification of phosphorylation in HDAC1 and
HDAC2 at indicated sites in inguinal white adipo-
cytes incubated with CK2-VIII in the presence or
absence of forskolin at 10 mM.
(G) Conservation of phosphorylation sites on
HDAC1 and HDAC2 in human, mouse, rabbit, and
chicken.
(H) Ucp1 and Elovl3 mRNA expression in inguinal
white adipocytes incubated with CK2-VIII in the
presence or absence of Mocetinostat at 150 nM
and Tubastatin at 150 nM for 4 days. Differentiated
adipocytes were treated with 10 mM forskolin for
4 hr. n = 3. **p < 0.01, ***p < 0.001 by one-sided
Student’s t test.that is one of the class II HDACs but not a CK2 substrate in
adipocytes. As shown in Figure 4H, CK2-VIII treatment
induced Ucp1 expression when adipocytes were stimulated
with forskolin. Such increase was largely blunted when cells
were co-treated with Mocetinostat. In contrast, the CK2 inhibi-
tor-induced Ucp1 expression was not affected in cells co-
treated with Tubastatin. Similarly, the CK2 inhibitor’s effect
on Elovl3 expression was not seen when cotreated with
Mocetinostat (Figure 4H). These results indicate that reduced
phosphorylation of class I HDACs mediates a large part of the
CK2 inhibitor’s effects on the thermogenetic gene program in
adipocytes.
Pharmacological Blockade of CK2 Stimulates
UCP1-Dependent Thermogenesis and Ameliorates
Diet-Induced Obesity and Insulin Resistance
Since a functional hallmark of brown/beige fat is cold-stimulated
thermogenesis, we asked if pharmacological inhibition of CK21002 Cell Metabolism 22, 997–1008, December 1, 2015 ª2015 Elsevalters whole-body energy expenditure under cold. To this end,
we measured whole-body oxygen consumption rate (VO2)
in mice treated with vehicle or CX-4945 for 5 days under dif-
ferent environmental temperatures. While VO2 levels were not
affected by CX-4945 treatment at thermoneutrality (30C), the
CX-4945-treated mice exhibited significantly higher energy
expenditure when mice were housed progressively under cold
(Figure 5A). For instance, VO2 levels of CX-4945-treated mice
were higher than vehicle-treated mice by 8% and 11.8% under
10C and 4C, respectively. This increase in energy expenditure
was independent of food consumption and behavior (Fig-
ure S4A). Importantly, the increase in VO2 level by CX-4945
was completely blunted in Ucp1 null mice (Figure 5B), suggest-
ing that a large part of the increased energy expenditure by
CK2 inhibition depends on UCP1-mediated thermogenesis,
rather than heat loss.
To examine therapeutic potential of pharmacological CK2 inhi-
bition on diet-induced obesity in vivo, C57BL/6J male mice wereier Inc.
Figure 5. CK2 Blockade Stimulates UCP1-
Dependent Thermogenesis and Ameliorates
Diet-Induced Obesity and Insulin Resis-
tance
(A) VO2 of mice treated with vehicle and CX-4945
at indicated temperature. n = 5. p values were
determined by repeated-measures ANOVA.
(B) VO2 of wild-type (left) and Ucp1 null mice
(right) treated with vehicle and CX-4945 under
22C. n = 5.
(C) Body weight of mice after treated with vehicle
or CX-4945 for 40 days under a high-fat diet. n = 6.
(D) Body fat percentage (left) and lean mass (right)
of mice in (C) as assessed by Echo-MRI.
(E) Weight of adipose tissues of mice in (C).
(F) Glucose tolerance test in mice in (C). AUC is
shown in the right panel.
(G) Insulin tolerance test in mice in (C). AUC is
shown in the right panel.
(H) Fasting plasma insulin concentration in obese
mice treated with vehicle or CX-4945 for 40 days
under a high-fat diet. n = 5.
(I) H & E staining of liver from mice treated with
vehicle or CX-4945 for 40 days under a high-fat
diet. Scale bar, 100 mm.
(J) Liver triglyceride contents in mice in (I). n = 5
*p < 0.05, **p < 0.01 by one-sided Student’s t test.fed a high-fat diet for 16 weeks and subsequently treated with
vehicle or CX-4945 at 50 mg kg1 over a period of 40 days.
Consistent with the timing of WAT browning by CX-4945 in vivo,
a significant decrease in body weight gain was observed at
10 days of CX-4945 treatment and thereafter (Figure S4B).
Long-term treatment with CX-4945 was effective to prevent
diet-induced body weight gain (Figure 5C). Echo-MRI analysis
showed that CX-4945 treatment significantly reduced body fat
mass without affecting lean body mass (Figure 5D). CX-4945
treatment significantly reduced adipose mass of the epididymal
and inguinal WAT depots (Figure 5E).
We further examined if a reduced body weight gain by CK2 in-
hibition leads to an improvement in systemic glucose homeosta-
sis. Glucose tolerance test (GTT) found that mice treated with
CX-4945 exhibited moderately but significantly lower blood
glucose levels than vehicle-treatedmice (Figure 5F). Insulin toler-
ance test (ITT) showed that CX-4945 treated mice displayed
significantly improved response to insulin (Figure 5G) and lower
serum insulin levels under a fasted state (Figure 5H) than vehicle-Cell Metabolism 22, 997–1008, Dtreated mice. Since recent studies indi-
cate a close connection between BAT
thermogenesis and hepatic lipid meta-
bolism (Bartelt et al., 2011; Cohen et al.,
2014; Ohno et al., 2013), we examined
the liver phenotype of mice treated with
CX-4945. We found that the liver from
mice treated with CX-4945 contained
significantly lower amounts of lipid
droplets (Figure 5I) and triglyceride (Fig-
ure 5J), as compared to vehicle-treated
mice. These results indicate that pharma-
cological CK2 inhibition ameliorates diet-induced obesity and insulin resistance by promoting UCP1-
dependent thermogenesis.
Antisense Oligonucleotide-Based Depletion of CK2
Synergistically Promotes Beige Adipocyte Biogenesis
under Mild Cold Exposure
We employed antisense oligonucleotide (ASO) as an alternative
approach to selectively block CK2 in vivo. When wild-type mice
were treated with ASO targeting Ck2a1 (Ck2-ASO) or control
ASO at 40 mg kg1 twice a week, Ck2a1 mRNA level was
significantly reduced by 70% in inguinal WAT, while expression
of Ck2a2 and Ck2beta was unaffected (Figure 6A). The reduc-
tion in Ck2a1 mRNA level resulted in a decrease in the protein
level of CK2a1 (Figure 6B) and reduction in CK2 activity by
approximately 50% (Figure 6C). Furthermore, mice treated
with the Ck2-ASO displayed a significant increase in whole-
body energy expenditure when mice were treated with the
beta3-AR agonist CL 316,243 under thermoneutrality (Figures
6D and S5A).ecember 1, 2015 ª2015 Elsevier Inc. 1003
Figure 6. ASO-Based Depletion of CK2
Synergistically Promotes Beige Adipocyte
Biogenesis under Mild Cold Exposure
(A) Expression of Ck2a1, Ck2a2, and Ck2b in the
inguinal WAT of mice treated with control or Ck2-
ASO. n = 9.
(B) Western blotting for CK2a1 in the inguinal WAT
in (A). b-actin was used as a loading control.
(C) CK2 activity in the inguinal WAT of mice treated
with control or Ck2-ASO. n = 5.
(D) VO2 of mice injected with control or Ck2-ASOs.
The mice were treated with saline or CL316,243 at
0.5 mg kg1 under thermoneutrality. n = 5.
(E) Expression of brown/beige fat-selective marker
genes in the inguinal WAT of mice treated with
control or Ck2-ASO under a high-fat diet. n = 5.
*p < 0.05, ***p < 0.001 by one-sided Student’s
t test.
(F) H&E staining of the inguinal WAT of mice in (E).
Lower-magnification images are shown in insets.
Scale bar, 50 mm.Based on these results, we hypothesized that a combination of
CK2 depletion and cold exposure may synergistically activate
the thermogenic program. To this end, Ck2a1 was depleted in
wild-type mice under a high-fat diet either at ambient tempera-
ture (22C) or mild cold temperature (17C). Consistent with
the previous results, Ucp1 mRNA in inguinal WAT was elevated
by 3-fold and 5-fold by Ck2-ASO treatment and mild cold expo-
sure, respectively. Notably, Ck2-ASO treatment under mild cold
exposure resulted in a robust increase inUcp1 expression by 43-
fold (Figure 6E). Expression of other brown/beige fat-selective
genes in the inguinal WAT, such as Cidea and Elovl3, followed
the similar trend, while expression of Fabp4 was not affected.
We also observed a moderate increase in the expression of
Ucp1, Pgc1a, Elovl3, and Cox7a1 in the interscapular BAT by
Ck2-ASO and mild cold exposure (Figure S5B). The modest
effect in the interscapular BAT depot may be due to lower CK2
activity in BAT than in WAT. Histological analysis of the inguinal
WAT depots found that Ck2-ASO and mild cold exposure
synergistically promoted the recruitment of multilocular and
UCP1-positive beige adipocytes (Figures 6F and S5C). These
data suggest that ASO-mediated CK2 depletion promotes
cold-induced thermogenesis in WAT.
ASO-Based CK2 Depletion Enhances Cold-Stimulated
Energy Metabolism and Ameliorates Diet-Induced
Obesity and Insulin Resistance
To examine the combinatorial effect of Ck2-ASO and mild cold
exposure on whole-body energy metabolism, C57BL/6J male
mice were fed with a high-fat diet and treated with control-
ASO or Ck2-ASO under 22C or 17C. As shown in Figure 7A,
Ck2-ASO treatment at 17C led to a 23% reduction of diet-
induced body weight gain as compared to control mice at
22C, whereas CK2-ASO or mild cold exposure alone reduced1004 Cell Metabolism 22, 997–1008, December 1, 2015 ª2015 Elsevier Inc.body weight gain by 13% and 12%,
respectively. No significant change in
food intake was detected between Con-
trol- and Ck2-ASO treated group (Fig-
ure 7B). The changes in body weightwas due to reduction in body fat mass, but not to changes in
lean mass (Figure 7C).
Lastly, we assessed if Ck2-ASO improves systemic glucose
homeostasis and hepatic lipid metabolism. While glucose toler-
ance was significantly improved in mice treated with Ck2-ASO,
such improvement was further enhanced under mild cold expo-
sure (Figures 7D and E). Insulin sensitivity was significantly
improved in mice treated with Ck2-ASO both under 22C and
17C (Figure 7F). Fasting insulin levels were significantly reduced
in mice treated with Ck2-ASO under 22C, while Ck2-ASO
treated mice under mild cold exposure displayed lower levels
of fasting insulin than control-ASO treated mice under 22C (Fig-
ure 7G). The liver from CK2-treated mice contained significantly
lower levels of TG under 22C and 17C (Figure 7H). Together,
these results indicate that ASO-mediated CK2 depletion leads
to a profound improvement in adiposity, systemic glucose ho-
meostasis, and hepatic lipid metabolism under a high-fat diet.
This metabolic improvement by the CK2 inhibition is further
enhanced by mild cold exposure.
DISCUSSION
Fromour unbiased phosphoproteomic analyses of brown, beige,
and white adipocytes, we unexpectedly found that the CK2
signaling pathway is activated preferentially in white fat in
response to cAMP stimuli and to an obesogenic diet. In the
phosphoproteome, we used two independent cellular models
of beige adipocytes that were induced by PRDM16 overexpres-
sion and chronic treatment with rosiglitazone. As a control for
each model, we used UCP1-negative white adipocytes that
were derived from the same source. This is because we are
aware of the possibility that difference(s) in a given kinase activity
is simply due to different source of cells, rather than functional
Figure 7. ASO-Based CK2 Depletion En-
hances Cold-Stimulated Metabolism and
Ameliorates Diet-Induced Obesity and Insu-
lin Resistance
(A) Changes in body weight of mice treated with
control or Ck2-ASOs under a high-fat diet. Mice
were housed under 22C or 17C. n = 9.
(B) Food intake in mice treated with control or Ck2-
ASOs in (A). Data are average of the first 2 weeks.
(C) Body fat percentage and lean mass in (A).
(D) GTT of mice treated with control or Ck2-ASOs
in (A).
(E) AUC of GTT in (D).
(F) ITT of mice treated with control or Ck2-ASOs
in (A).
(G) Fasting plasma insulin concentration of mice
in (A).
(H) Liver triglyceride contents in (A). *p < 0.05, **p <
0.01, ***p < 0.001 versus control by one-sided
Student’s t test.difference (i.e., thermogenesis). We found that CK2 activity is
consistently higher in UCP1-negative white adipocytes, as
compared to UCP1-postive brown/beige adipocytes in both
models. Of note, genetic or pharmacological inhibition of CK2
in white fat enhances the thermogenic program in response to
cAMP stimuli, while CK2 inhibition alone is not sufficient to do
so. These data indicate that CK2 function as a negative regulator
of cold/cAMP-induced thermogenesis in adipocytes.
The phosphoproteomics of CK2 substrates found a previously
unappreciated function of CK2 in thermogenesis through phos-
phorylation of class I HDACs. Intriguingly, the molecular link be-
tween class I HDACs and mitochondrial biogenesis has been
previously reported in skeletal muscle, cardiac muscle, and ad-
ipose tissue. As an example, cardiac-specific deletion of HDAC3
results in increased expression of mitochondrial OXPHOS genes
(Montgomery et al., 2008). Furthermore, pharmacological inhibi-
tion of class I HDACs by MS-275, a clinical stage HDAC1 inhib-Cell Metabolism 22, 997–1008, Ditor, enhances oxidative metabolism in
skeletal muscle and adipose tissues (Gal-
mozzi et al., 2013). Of note, the CK2 phos-
phorylation deficient mutant of HDAC1 at
serine 421 and serine 423 displayed
reduced enzymatic activity and repressor
complex formation with CoREST, MTA2,
RbAp48, and Sin3A (Pflum et al., 2001).
These observations indicate that inhibi-
tion of CK2-mediated phosphorylation
on class I HDACs mediates a large part
of the CK2 inhibitor’s action on thermo-
genesis in white adipocytes. Our phos-
phoproteomics also identified novel CK2
substrates that may contribute to the
CK2 inhibitor’s effects, such as TLE3,
PTEN, and PRDM16 that are previously
reported to control brown/beige adipo-
cyte development (Kajimura et al., 2009;
Ortega-Molina et al., 2012; Seale et al.,
2011, 2007; Villanueva et al., 2013). It ispossible that these CK2 targets may be involved in the regulation
of beige adipocyte biogenesis and thermogenesis via the CK2
pathway.
Because the b3-AR pathway plays a dominant role in stimu-
lating BAT thermogenesis, extensive efforts have been made
in the past to pharmacologically activate BAT thermogenesis
using the b-AR agonists in adult humans. While some adverse
effects on the cardiovascular system prevented the use of
b-AR agonist in the clinic (Villarroya and Vidal-Puig, 2013), a
recent study reported that oral administration of Mirabegron,
a selective b3-AR agonist, significantly stimulated glucose up-
take in the BAT depots in healthy adult humans who possess
active BAT depots before the treatment (Cypess et al., 2015).
Administration of a pan-adrenergic agonist (Ephedrine) also
activates BAT metabolic activity in lean subjects (Carey et al.,
2013). Given our results that CK2 inhibition enhances the
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stimuli even in diet-induced obese mice, it is conceivable that
coadministration of CK2 inhibitors and b3-AR agonists, such
as Mirabegron, may effectively activate BAT thermogenesis
even in subjects who possess lower sensitivity to b3-AR ago-
nists, such as obese and/or elderly populations.
EXPERIMENTAL PROCEDURES
Phosphoproteomics
Differentiated adipocytes were treated with norepinephrine at 1 mM. To deter-
mine the CK2 targets, inguinal white adipocytes were treated with CK2-VIII at
1 mM or vehicle (DMSO) for 4 days. The differentiated adipocytes were treated
with forskolin at 10 mM for 20 min. Phosphoproteins, isolated from the
collected adipocytes, were enriched by TiO2-based hydroxy acid-modified
metal oxide chromatography (HAMMOC) (Sugiyama et al., 2007). Phospho-
peptides were desalted by StageTips (Rappsilber et al., 2007) and suspended
in the loading buffer for subsequent nanoLC-MS/MS analyses.
For in vitro kinase substrate profiling, cell lysates from differentiated inguinal
white adipocytes were first dephosphorylated with phosphatase at 37C for
1 hr, followed by heat inactivation at 75C for 30 min. Subsequently, 100 mg
of the dephosphorylated proteins were reacted with recombinant CK2 (Carna
Biosciences) at 37C, and subsequently digested with Lys-C/trypsin. Phos-
phopeptides were analyzed by nanoLC–MS/MS system.
The phosphoproteome data were analyzed using AB Sciex MS Data Con-
verter to create peak lists based on the recorded fragmentation spectra.
Mascot v. 2.4 (Matrix Sciences) was used against SwissProt Database with
the parameters previously described (Yamana et al., 2013), except for a pre-
cursor mass tolerance of 10 ppm and a fragment ion mass tolerance of
0.1 Da. The data files from the Q-Exactive systemwere analyzed usingMascot
version 2.5.1 against SwissProt Database (version 2015_02) with a precursor
mass tolerance of 5 ppm and the fragment ion mass tolerance of 0.02 Da.
The number of phosphopeptides with motif was normalized to the number
at basal (time point 0). Statistical evaluation was based on this normalized
value using repeated-measures ANOVA. The MS proteomics data have
been deposited with the dataset identifier PXD002812.
Animals
All animal experiments were performed according to procedures approved by
UCSF’s Institutional Animal Care and Use Committee. Male C57BL/6J mice
at 4 weeks of age were fed with a regular diet (9% fat) or a high-fat diet
(60% kcal% fat) for 4–18 weeks. Ucp1/ mice in C57Bl/6J background
were derived from heterozygous breeding pairs.
Metabolic Studies
CX-4945 at 50 mg kg1 (Axon Medchem) was administered by oral gavage
twice daily for 5 days and up to 40 days. To assess the effects of CX-4945
on whole-body energy expenditure, vehicle or CX-4945 treated mice were
transferred to CLAMS chamber at 9 weeks of age. For cold challenge experi-
ments using CX-4945, male 6-week-old C57BL6/J mice under a regular diet
were acclimated to 30C for 2 weeks and administrated with vehicle or CX-
4945 for 5 days. The mice were transferred to CLAMS chamber and VO2/O2
were collected under 30C, 20C, 10C, and 4C. For in vivo delivery
of ASO, male 8-week-old C57BL/6J mice were IP-injected with control
(CCTTCCCTGAAGGTTCCTCC)- or Ck2-ASO (GTCTGTTAACGTCTGGTACA)
at 40 mg kg1 twice a week. To assess the metabolic effects of CX-4945 or
Ck2-ASO, male obese C57BL/6J mice were fed a high-fat diet (60% fat). For
GTT, the mice were injected intraperitoneally with glucose (2 g kg1) after
6 hr fasting. For ITT, the mice were injected intraperitoneally with insulin
(0.75 U kg1).
CK2 Activity Assay
CK2 kinase activity assay was performed as described previously (Ruzzene
et al., 2010) with minor modifications. Ten mg of protein lysates were incubated
with CK2-substrate peptide (Millipore) at 30C for 10 min in a kinase assay
buffer (Millipore) in the presence of PKA inhibitors and 10 mM [g-32P]ATP
(PerkinElmer). We observed a tight linear correlation (R2 > 0.99) between the
amounts of protein used in the assays and the CK2 activity.1006 Cell Metabolism 22, 997–1008, December 1, 2015 ª2015 ElsevRNAi Knockdown
SMARTpool ON-TARGETplus siRNA for Ck2a1 (NM_007788), Ck2a2
(NM_009974) and Ck2b (NM_009975) were obtained from GE Dharmacon.
Nontargeting siRNA was used as a control. Preadipocytes were reverse trans-
fected with siRNA using Lipofectamine RNAiMAX. Adipocyte differentiation
was induced by treating confluent cells in Advanced DMEM/F-12 (Life Tech-
nologies) containing 10% FBS, 0.5 mM isobutylmethyl-xanthine, 125 mM
dexamethasone, 2 mg ml-1 dexamethasone, 850 nM insulin, 1 nM T3, and
1 mM rosiglitazone. Two days after induction, cells were further incubated in
a maintenance medium containing 10% FBS, 850 nM insulin, and 1 nM T3
for for 3.5 days. For cAMP treatment, cells were incubated with 10 mM forskolin
for 4 or 8 hr for RNA and protein analyses, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and three tables and can be
found with this article at http://dx.doi.org/10.1016/j.cmet.2015.09.029.
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